Evidence map›Paper›PMID 36793509›Full record

ArticleAdvances in radiation oncology

Calreticulin Upregulation in Cervical Cancer Tissues From Patients After 10 Gy Radiation Therapy.

Kohei Okada, Hiro Sato, Takuya Kumazawa, Yasumasa Mori, Tiara Bunga Mayang Permata, Yuki Uchihara, Shin-Ei Noda, Keiji Suzuki, Hayato Ikota, Hideaki Yokoo and 4 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Kohei OkadaDepartment of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Hiro SatoDepartment of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Takuya KumazawaDepartment of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Yasumasa MoriNational Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Anagawa, Inage, Chiba, Japan.
Tiara Bunga Mayang PermataDepartment of Radiation Oncology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
Yuki UchiharaSignal Transduction Program, Gunma University Initiative for Advanced Research (GIAR), Gunma University, Maebashi, Gunma, Japan.
Shin-Ei NodaDepartment of Radiation Oncology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Keiji SuzukiDepartment of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, Sakamoto, Nagasaki, Japan.
Hayato IkotaClinical Department of Pathology, Gunma University Hospital, Maebashi, Gunma, Japan.
Hideaki YokooDepartment of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Soehartati GondhowiardjoDepartment of Radiation Oncology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
Takashi NakanoNational Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Anagawa, Inage, Chiba, Japan.
Tatsuya OhnoDepartment of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Atsushi ShibataSignal Transduction Program, Gunma University Initiative for Advanced Research (GIAR), Gunma University, Maebashi, Gunma, Japan.
Gunma University · JPNational Institutes for Quantum Science and Technology · JPUniversity of Indonesia · IDGunma University Hospital · JPNagasaki University · JPSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Understanding the immune response during radiation therapy (RT) in a clinical setting is imperative for maximizing the efficacy of combined RT and immunotherapy. Calreticulin, a major damage-associated molecular pattern that is exposed on the cell surface after RT, is presumed to be associated with the tumor-specific immune response. Here, we examined changes in calreticulin expression in clinical specimens obtained before and during RT and analyzed its relationship with the density of CD8 Methods and Materials: This retrospective analysis evaluated 67 patients with cervical squamous cell carcinoma who were treated with definitive RT. Tumor biopsy specimens were collected before RT and after 10 Gy irradiation. Calreticulin expression in tumor cells was evaluated via immunohistochemical staining. Subsequently, the patients were divided into 2 groups according to the level of calreticulin expression, and the clinical outcomes were compared. Finally, the correlation between calreticulin levels and density of stromal CD8 Results: The calreticulin expression significantly increased after 10 Gy (82% of patients showed an increase; Conclusions: Calreticulin expression increased after 10 Gy irradiation in tissue biopsies of patients with cervical cancer. Higher calreticulin expression levels are potentially associated with better progression-free survival and greater T cell positivity, but there was no statistically significant relationship between calreticulin upregulation and clinical outcomes or CD8

Identifiers

PMID36793509
PMCPMC9922916
OpenAlexW4313254752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.